Beta-CIT-SPECT and Neurophysiology in Depression

Phase 4

Completed

• Conditions: Depression

• Registration Number: NCT00145132
• Lead Sponsor: Ludwig-Maximilians - University of Munich

Brief Summary

Aim of this project is to investigate the effects of escitalopram on monoamine transporter (SERT, DAT) availabilities as assessed by b-CIT and SPECT, and on neurophysiological parameters such as the loudness dependence of auditory evoked potentials (LDAEP) in patients with depression.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06
• Study First Submitted: 2005-09-01
• Study First Submitted QC: 2005-09-01
• Study First Posted: 2005-09-05
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Status Verified: 2010-05
• Last Update Submitted: 2010-06-01
• Last Update Posted: 2010-06-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Psychiatric in or outpatients with acute depressive episode
• Indication for pharmacological treatment

Exclusion Criteria

• Acute suicidality
• Neurological or severe somatic disorders
• Occupational exposition to radiation >15 mSv per year
• Women during pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
changes in β-CIT/neurophysiological measurements from baseline to week 4	two assessments, at baseline and week 4

Trial Locations

Locations (1)

Depts. of Psychiatry and Nuclear Medicine, Ludwig-Maximilians-University of Munich; 🇩🇪 Munich, Germany